Chemical Name: Galanthamine.
Cas Number: 1953-04-4
Molecular formula: C17H21NO3.HBr;C17H22BrNO3
Molecular Weight: 287.36
Original Plant:Lycoris radiata (LHer.) Herb.
Assay: Galanthamine 99% min
Assayed by: HPLC
Test Item:Appearance, Identification, Residue on Ignition, Specific Rotation, Loss on drying, pH, Solvent Residual, Assay, Ralated Substances
Packing: Nt.W:1kg/aluminum foil bag with inner plastic bag
Storage: Store in a cool and dry area, keep sealed and keep away from direct light
Our product is extracted from the tuberous plant Shorttube Lycoris (botanical name as Lycoris radiata (L.Herit.) Herb.). It is manufactured as galantamine ( galanthamine ) hydrobromide.It is used in the manufacturing of the medication Nivalin and Reminyl which was approved by FDA, they are a strong (reversible) cholinesterase inhibitor, increasing the susceptibility of the organism to acetylcholine, and treat for mild to moderate dementia of the Alzheimer's type in clinic.
The drug galantamine is much inadequate for patient's consumption around the world, because there is a little valuable galantamine in some plants of Amaryllidaceae family. We have extensively planted the herbs and adopted advanced extract technology, for both enhancing the yield and purifying fine products.
Galanthamine extract is specific, competitive and reversible acetylcholinesterase inhibitor. It is also an allosteric modulator at nicotinic cholinergic receptor sites potentiating cholinergic nicotinic neurotransmission. Both the acetylcholine and nicotine receptors have been suggested as areas related to cognitive impairment. Initially, Galanthamine extract was used in anesthesiology to antagonize the effects of non-depolarizing muscle relaxants, and since then it was rapidly introduced in other areas of medicine, i.e. neurology, ophthalmology, gastroenterology, intensive care and resuscitation, cardiology, physiotherapy.
Galanthamine extract is a product with broad therapeutic index, allowing "soft" manifestation of its effect with individual dosing depending on the particular case.
Several trials already showed that Galantamine 16 and 24 mg/day significantly benefits the cognitive, functional, and behavioral symptoms of AD as compared with placebo and proved also to be very effective in symptomatic treatment of senile dementia of Alzheimer's type
Galanthamine marketed under the name of Reminyl by Johnson & Johnson's Belgian subsidiary, Janssen Pharmaceutica and Britain's Shire Pharmaceuticals, is licensed for the treatment of mild to moderately severe Alzheimer's disease, and was launched in September 2000 and approved by FDA in Feb.2001.
Now, Galanthamine has received regulatory approval in 29 counties: Argentina, Australia, Canada, Czechia, the European Union (except for The Netherlands), Iceland, Korea, Mexico, Norway, Poland, Singapore, South Africa, Switzerland, Thailand, and the United States.